- Home
- BMRA vs CVKD Comparison
BMRA vs CVKD Comparison
Compare BMRA & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMRA
- CVKD
- Stock Information
- Founded
- BMRA 1971
- CVKD 2022
- Country
- BMRA United States
- CVKD United States
- Employees
- BMRA N/A
- CVKD N/A
- Industry
- BMRA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- BMRA Health Care
- CVKD Health Care
- Exchange
- BMRA Nasdaq
- CVKD Nasdaq
- Market Cap
- BMRA 7.4M
- CVKD 17.1M
- IPO Year
- BMRA N/A
- CVKD 2023
- Fundamental
- Price
- BMRA $0.33
- CVKD $15.24
- Analyst Decision
- BMRA
- CVKD Strong Buy
- Analyst Count
- BMRA 0
- CVKD 2
- Target Price
- BMRA N/A
- CVKD $52.50
- AVG Volume (30 Days)
- BMRA 68.2K
- CVKD 59.6K
- Earning Date
- BMRA 10-15-2024
- CVKD 11-08-2024
- Dividend Yield
- BMRA N/A
- CVKD N/A
- EPS Growth
- BMRA N/A
- CVKD N/A
- EPS
- BMRA N/A
- CVKD N/A
- Revenue
- BMRA $5,509,000.00
- CVKD N/A
- Revenue This Year
- BMRA N/A
- CVKD N/A
- Revenue Next Year
- BMRA N/A
- CVKD N/A
- P/E Ratio
- BMRA N/A
- CVKD N/A
- Revenue Growth
- BMRA 1.74
- CVKD N/A
- 52 Week Low
- BMRA $0.24
- CVKD $5.40
- 52 Week High
- BMRA $2.13
- CVKD $32.55
- Technical
- Relative Strength Index (RSI)
- BMRA 47.85
- CVKD 60.90
- Support Level
- BMRA $0.28
- CVKD $11.19
- Resistance Level
- BMRA $0.35
- CVKD $15.93
- Average True Range (ATR)
- BMRA 0.04
- CVKD 1.36
- MACD
- BMRA 0.00
- CVKD 0.23
- Stochastic Oscillator
- BMRA 41.67
- CVKD 61.01
About BMRA Biomerica Inc.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates in one segment namely, the design, development, marketing and sales of diagnostic kits. The majority of the company's revenue is earned from the Europe market.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.